Display options
Cite
Nakagami H, Koriyama H, Morishita R. Peptide Vaccines for Hypertension and Diabetes Mellitus. Vaccines (Basel). 2014;2(4):832-40doi: 10.3390/vaccines2040832.
Nakagami, H., Koriyama, H., & Morishita, R. (2014). Peptide Vaccines for Hypertension and Diabetes Mellitus. Vaccines, 2(4), 832-40. https://doi.org/10.3390/vaccines2040832
Nakagami, Hironori, et al. "Peptide Vaccines for Hypertension and Diabetes Mellitus." Vaccines vol. 2,4 (2014): 832-40. doi: https://doi.org/10.3390/vaccines2040832
Nakagami H, Koriyama H, Morishita R. Peptide Vaccines for Hypertension and Diabetes Mellitus. Vaccines (Basel). 2014 Nov 26;2(4):832-40. doi: 10.3390/vaccines2040832. PMID: 26344893; PMCID: PMC4494253.
Copy Download .nbib Format: NLM
Share it on

Vaccines (Basel). 2014 Nov 26;2(4):832-40. doi: 10.3390/vaccines2040832.

Peptide Vaccines for Hypertension and Diabetes Mellitus.

Vaccines

Hironori Nakagami, Hiroshi Koriyama, Ryuichi Morishita

Affiliations

  1. Division of Vascular Medicine and Epigenetics, Osaka University United Graduate School of Child Development, Osaka University, Kanazawa University and Hamamatsu University School of Medicine, Chiba University, Fukui University, 2-1 Yamada-oka, Suita, Osaka 565-0871, Japan. [email protected].
  2. Division of Vascular Medicine and Epigenetics, Osaka University United Graduate School of Child Development, Osaka University, Kanazawa University and Hamamatsu University School of Medicine, Chiba University, Fukui University, 2-1 Yamada-oka, Suita, Osaka 565-0871, Japan. [email protected].
  3. Department of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan. [email protected].

PMID: 26344893 PMCID: PMC4494253 DOI: 10.3390/vaccines2040832

Abstract

Vaccines are commonly used as a preventive medicine for infectious diseases worldwide; however, the trial for an amyloid beta vaccine against Alzheimer's disease will open a new concept in vaccination. In case of therapeutic vaccines for cancer, their targets are usually specific antigens in cancer cells, allowing activated cytotoxic T cells (CTLs) to attach and remove the antigen-presenting cancer cells. In our therapeutic vaccines against hypertension, the target is angiotensin II (Ang II) and induced anti-Ang II antibodies could efficiently ameliorate high blood pressure. Similarly, we developed the therapeutic vaccine against DPP4 for diabetes mellitus. However, because Ang II or DPP4 is an endogenous hormone, we must avoid autoimmune disease induced by these vaccines. Therefore, our system was used to design a therapeutic vaccine that elicits anti-Ang II or DPP4 antibodies without CTL activation against Ang II or DPP4. In this review, we will describe our concept of therapeutic vaccines for hypertension and diabetes mellitus.

Keywords: DPP4; angiotensin II; vaccine

References

  1. Adv Ther. 2009 May;26(5):488-99 - PubMed
  2. Endocrinology. 1995 Aug;136(8):3585-96 - PubMed
  3. Circ Res. 1975 Dec;37(6):715-24 - PubMed
  4. Hypertension. 2013 Feb;61(2):408-16 - PubMed
  5. Clin Sci (Lond). 2004 Aug;107(2):167-73 - PubMed
  6. Cancer Biother Radiopharm. 2011 Feb;26(1):1-64 - PubMed
  7. Neurology. 2003 Jul 8;61(1):46-54 - PubMed
  8. Circulation. 1958 Apr;17(4, Part 2):653-7 - PubMed
  9. Diabetes. 1999 May;48(5):1045-53 - PubMed
  10. PLoS One. 2013;8(3):e60493 - PubMed
  11. J Hypertens. 2007 Jan;25(1):63-72 - PubMed
  12. Proc Natl Acad Sci U S A. 1987 Jun;84(12):4346-50 - PubMed
  13. Swiss Med Wkly. 2010 Nov 01;140:w13108 - PubMed
  14. Lancet. 2002 Mar 9;359(9309):824-30 - PubMed
  15. Gastroenterology. 2007 May;132(6):2131-57 - PubMed
  16. Br J Pharmacol. 2000 Mar;129(6):1178-82 - PubMed
  17. Circulation. 1958 Apr;17(4, Part 2):648-52 - PubMed
  18. Diabetes Care. 2006 Dec;29(12):2632-7 - PubMed
  19. Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):E1256-63 - PubMed
  20. Circ Res. 1963 Mar;12:241-55 - PubMed
  21. Lancet. 2006 Nov 11;368(9548):1696-705 - PubMed
  22. Circulation. 1990 Jun;81(6):1899-910 - PubMed
  23. J Exp Med. 1964 Mar 1;119:425-32 - PubMed
  24. Lancet. 2008 Mar 8;371(9615):821-7 - PubMed
  25. Circ Res. 1957 Mar;5(2):137-43 - PubMed
  26. Nature. 1999 Jul 8;400(6740):173-7 - PubMed
  27. Nat Rev Neurosci. 2002 Oct;3(10):824-8 - PubMed
  28. Nat Med. 2003 Apr;9(4):448-52 - PubMed
  29. Nature. 2000 Dec 21-28;408(6815):982-5 - PubMed
  30. PLoS One. 2013 Jun 25;8(6):e66420 - PubMed
  31. Brain Pathol. 2004 Jan;14(1):11-20 - PubMed

Publication Types